2-(2,2-二乙氧基乙氧基)-1,1-二乙氧基乙烷 | 56999-16-7

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(2,2-二乙氧基乙氧基)-1,1-二乙氧基乙烷
• 中文别名: 1,1-二乙氧基-2-(2,2-二乙氧基乙氧基)乙烷
• 英文名称: 2-(2,2-diethoxyethoxy)-1,1-diethoxyethane
• 英文别名: bis-(2,2-diethoxy-ethyl) ether；oxy-bis-acetaldehyde bis-(diethyl acetal)；1,1'-oxybis(2,2-diethoxyethane)；2,2'-oxydiacetaldehyde bis (diethyl) acetal；2-(2,2-diethoxy-ethoxy)-1,1-diethoxy-ethane；bis(2,2-diethoxyethyl)ether
• CAS: 56999-16-7
• 化学式: C₁₂H₂₆O₅
• 分子量: 250.335
• InChiKey: ISSXEHJFYXCGSK-UHFFFAOYSA-N

物化性质

• 沸点：
  150-155 °C(Press: 30 Torr)
• 密度：
  0.965±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1,1’-Oxybis[2,2-diethoxyethane]
Synonyms: 2-(2,2-Diethoxyethoxy)-1,1-diethoxyethane

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1,1’-Oxybis[2,2-diethoxyethane]
CAS number: 56999-16-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H26O5
Molecular weight: 250.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-oxopentanedioic acid 、 2-(2,2-二乙氧基乙氧基)-1,1-二乙氧基乙烷 在 盐酸 、 盐酸甲胺 、 柠檬酸 作用下， 以 水 、 溶剂黄146 为溶剂， 生成 9-甲基-7-氧杂-9-氮杂双环[3.3.1]壬烷-3-酮
  参考文献：
  名称：

  Bicyclic amine derivatives

  摘要：

  式(I)的化合物：其中A代表具有式--CH.sub.2 --X--CH.sub.2 --（其中X为亚甲基、硫或氧）的双齿基团，X'C.dbd.CY或X'WC--CYZ（其中X'、W、Y和Z独立地为氢、羟基、酰氧基、烷氧基、烷基硅氧基、氰基或卤素，或者X'和W或Y和Z与它们连接的碳共同形成羰基），前提是A不是CH.sub.2 --CH.sub.2；Ar是一个可选取代的苯基或含有1至3个异原子（分别选自氮、氧和硫原子）的5或6元杂环环系统，且环中相邻原子之间至少有一个不饱和度（双键），所述杂环环可选地与苯环融合；芳基、杂芳基、芳基烷基、杂芳基烷基、烯基、芳基烯基、炔基、烷氧羰基、烷磺酰基、芳磺酰基、烷氧羰基、芳基烷氧羰基、芳氧羰基、杂环烷基、氨基、二硫代羧酸酯基团的R、R.sup.3和R.sup.4由1至15个碳原子组成，并且可选地取代为一个或多个卤素、氰基、羧基、羧酰基、氨基、烷氧羰基、烷氧基、烷二氧基、羟基、硝基、卤代烷基、烷基、氨基、酰胺基、亚胺酯和膦酸盐基团；或其酸加合盐、季铵盐或N-氧化物；一种含有式(I)化合物的杀虫剂、杀螨剂或杀线虫剂组合物，以及适当的载体或稀释剂；一种用于对抗和控制昆虫、螨虫或线虫害虫的方法，包括用有效量的式(I)化合物或前述的组合物处理害虫或害虫的场所。

  公开号：

  US05968947A1
• 作为产物：
  描述：

  2-溴-1,1-二乙氧基乙烷 、 2,2-二乙氧基乙醇 在 sodium hydride 作用下， 以 xylene 为溶剂， 反应 2.0h， 以42%的产率得到2-(2,2-二乙氧基乙氧基)-1,1-二乙氧基乙烷
  参考文献：
  名称：

  [EN] BICYCLIC PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR1 CHEMOKINE RECEPTOR
  [FR] DERIVES DE PIPERIDINE BICYCLIQUES UTILISES COMME ANTAGONISTES DU RECEPTEUR DE CHIMIOKINE CCR1

  摘要：

  一种具有如上所定义的a、b、c、R1、R2、R3、R4、R5、R6、Q、W、Y和Z的化合物，用作MIP-1α（CCL3）与其受体CCR1结合的有效且选择性抑制剂，该受体存在于炎症和免疫调节细胞上（最好是白细胞和淋巴细胞）。

  公开号：

  WO2004009588A1

文献信息

• Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation
  申请人：Malamas Sotirios Michael

  公开号：US20070027199A1

  公开（公告）日：2007-02-01

  The present invention provides a 2-amino-5-cycloalkyl-hydantoin compound of formula I The present invention also provides methods and compositions for the inhibition of β-secretase (BACE) and the treatment of β-amyloid deposits and neurofibrillary tangles.

  本发明提供了一种公式I的2-氨基-5-环烷基乙内酰脲化合物。 本发明还提供了一种用于抑制β-分泌酶（BACE）以及治疗β-淀粉样蛋白沉积和神经纤维缠结的方法和组合物。
• Reactions between diglycolaldehyde dithioacetals and some nucleophiles
  作者：F.J.Lopez Aparicio、F.Zorrilla Benitez、F.Santoyo Gonzalez

  DOI：10.1016/s0008-6215(00)85929-7

  日期：1981.4

  As part of a study’ of derwatwes of dlglycolaldehyde (2,2’-ouyblsacetaldehyde), the renctlon between dwJycolaldehyde bls(dlethy1 dlthloacetal)’ ’ (1) and alcohols has been studled The acychc (2a-d) and cychc (3a-b) products are noted m Table I Primary alcohols gave only the acychc acetals 2a-c, 2-propanol gave both acychc (2d) and cychc (3a) acetals, and rerf-butyl alcohol gave the cyc11c acetal 3b

  作为对二甘醇醛（2,2'-ouybsacetaldehyde）的皮肤的研究的一部分，己二醛（dwJycolaldehyde bls（dlethy1 dlthloacetal）''（1）和醇之间的反义已被研究。 b）在表I中注明了产品。表I伯醇仅给出了acychc缩醛2a-c，2-丙醇给出了acychc（2d）和cychc（3a）缩醛，而叔丁醇给出了cyc11c缩醛3b低收率所有通过与真实样品的比较确定了产品2酰基缩醛2d似乎不是中间体3a的中间体，因为它不与2-丙醇反应环己缩醛4可以转化为酰基bls（ dlmcthy1乙缩醛）''2a由甲醇-H＆l，-HgO反应生成，它不与汞反应
• Synthesis and structures of some diglycolaldehyde thioacetals
  作者：F.J. Lopez Aparicio、F. Zorrilla Benitez、F. Santoyo Gonzalez

  DOI：10.1016/s0008-6215(00)88051-9

  日期：1982.4

  α-substitution of the thiol. The acyclic dithioacetal 2a was the only product isolated when methanethiol was used, but mixtures of acyclic dithioacetals, cis -2,6-bis(alkylthio)-1,4-dioxanes, and trans -2,6-bis(alkylthio)-1,4-dioxanes were obtained when ethanethiol, 1-propanethiol, and 2-propanethiol were used. From 1a and 2-methylpropane-2-thiol, the acyclic dithioacetal 2e and the cis (7) and trans (8) stereoisomers

  摘要二甘醇醛（2,2'-oxybisacetaldehyde，1a）在类似于单糖的条件下与硫醇反应。反应产物的性质取决于硫醇的α-取代程度。无环二硫缩醛2a是使用甲硫醇时唯一分离出的产物，但无环二硫缩醛，顺式-2,6-双（烷硫基）-1,4-二恶烷和反式-2,6-双（烷硫基）-1的混合物当使用乙硫醇，1-丙硫醇和2-丙硫醇时，获得了4-4-二恶烷。从1a和2-甲基丙烷-2-硫醇中，分离出无环二硫缩醛2e和3,5-双（叔丁硫基）-1,4-氧杂蒽的顺式（7）和反式（8）立体异构体。另一方面，当在酸性介质中用伯硫醇或仲硫醇对二甘醇醛双（二烷基乙缩醛）（9a–d）或2,6-二异丙氧基-1,4-二恶烷（10）进行处理时，分离出无环二硫缩醛作为唯一产物。当在上述条件下用2-甲基丙烷-2-硫醇处理9a-d或10时，获得了无环二硫缩醛2e和oxathiane衍生物7和8。
• [EN] 3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES<br/>[FR] DÉRIVÉS DE 3-OXA-8-AZABICYCLO [3.2.1] OCTANE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER ET D'HÉMOGLOBINOPATHIES
  申请人：CTXT PTY LTD

  公开号：WO2017153519A1

  公开（公告）日：2017-09-14

  A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and(iv) CH 2 OH;R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH,-NH 2, -C(=O)NH 2, and -CH 2 OH; R 4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1;R 11a, R 11b, R 11c and R 11d are independently selected from H, halo, C1-4 alkyl, C 1-4 fluoroalkyl, C 3-4 cycloalkyl, C 1-4 alkyloxy, NH-C 1-4 alkyl and cyano; R 12a and R 12b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH 2 OH; R 12c and R 12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH;R 12e is H or Me; R 13a and R 13b are independently selected from H and Me; R 14 is either H or Me; R 16a and R 16b are independently selected from H and Me; R 6 is selected from H, OMe, and OEt.

  公式Ia、Ib、Ic或Id的化合物：其中：n为1或2；RN为H或Me；R1是可选的一个或多个卤素或甲基基团；R2a和R2b分别选自以下群体中的一种：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d（如果存在）分别选自以下群体中的一种：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4a选自OH、-NH2、-C(=O)NH2和-CH2OH；R4b为H或Me；R5为H或Me；m为1或2；q为0或1；R11a、R11b、R11c和R11d分别选自H、卤素、C1-4烷基、C1-4氟代烷基、C3-4环烷基、C1-4烷氧基、NH-C1-4烷基和氰基；R12a和R12b分别选自以下群体中的一种：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R12c和R12d分别选自以下群体中的一种：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R12e为H或Me；R13a和R13b分别选自H和Me；R14为H或Me；R16a和R16b分别选自H和Me；R6选自H、OMe和OEt。
• Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension
  申请人：——

  公开号：US20010046982A1

  公开（公告）日：2001-11-29

  Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.

  PGF系列的前列腺素化合物的新衍生物，特别是fluprostenol和相关的PGF类似物的环状内部1,15-内酯，如cloprostenol或latanoprost。这些新的类似物可以制成眼科溶液，并局部应用于治疗由青光眼引起的眼内压增高和减少眼压。